Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (113)
Cancellation by sponsor (63)
Australian Public Assessment Report (AusPAR) (44)
Prescription medicine registration (42)
Designation or determination (21)
Prescription medicine evaluation (15)
Prescription medicine decision summary (11)
Section 14, TGO91 consent (1)

Date

2024 (37)
2023 (32)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (10)
2012 (3)
2011 (6)
2010 (4)
2008 (3)
2007 (1)
2006 (8)
2004 (2)
2003 (5)
2002 (3)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Results for "[search-keyword]"

Search

Sponsor content

310 result(s) found, displaying 81 to 90

ENHERTU (AstraZeneca Pty Ltd)

12 July 2022

Prescription medicine registration

Active ingredients: trastuzumab deruxtecan.
VISACOR rosuvastatin (as calcium) 40mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VISACOR rosuvastatin (as calcium) 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VISACOR rosuvastatin (as calcium) 10mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AFFORA rosuvastatin (as calcium) 10mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AFFORA rosuvastatin (as calcium) 5mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VIBRENT rosuvastatin (as calcium) 40mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
TALEXAR rosuvastatin (as calcium) 10mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
TALEXAR rosuvastatin (as calcium) 5mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
NEXIUM Hp7 esomeprazole tablet, amoxicillin capsule, clarithromycin tablet composite pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.